KalVista Pharmaceuticals, Inc. (KALV): Price and Financial Metrics


KalVista Pharmaceuticals, Inc. (KALV): $28.03

-1.88 (-6.29%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

KALV POWR Grades


  • Value is the dimension where KALV ranks best; there it ranks ahead of 49.95% of US stocks.
  • The strongest trend for KALV is in Stability, which has been heading down over the past 31 weeks.
  • KALV's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).

KALV Stock Summary

  • The ratio of debt to operating expenses for KalVista Pharmaceuticals Inc is higher than it is for about only 6.46% of US stocks.
  • With a price/sales ratio of 181.29, KalVista Pharmaceuticals Inc has a higher such ratio than 97.42% of stocks in our set.
  • As for revenue growth, note that KALV's revenue has grown -67.57% over the past 12 months; that beats the revenue growth of just 3.82% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to KalVista Pharmaceuticals Inc are MRUS, GSIT, AUTL, CERC, and AMSC.
  • Visit KALV's SEC page to see the company's official filings. To visit the company's web site, go to www.kalvista.com.

KALV Price Target

For more insight on analysts targets of KALV, see our KALV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $55.71 Average Broker Recommendation 1.29 (Strong Buy)

KALV Stock Price Chart Interactive Chart >

Price chart for KALV

KALV Price/Volume Stats

Current price $28.03 52-week high $45.00
Prev. close $29.91 52-week low $9.62
Day low $27.57 Volume 1,511,900
Day high $30.15 Avg. volume 700,169
50-day MA $26.12 Dividend yield N/A
200-day MA $22.03 Market Cap 684.58M

KalVista Pharmaceuticals, Inc. (KALV) Company Bio


KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. The company is based in Cambridge, Massachusetts.


KALV Latest News Stream


Event/Time News Detail
Loading, please wait...

KALV Latest Social Stream


Loading social stream, please wait...

View Full KALV Social Stream

Latest KALV News From Around the Web

Below are the latest news stories about KalVista Pharmaceuticals Inc that investors may wish to consider to help them evaluate KALV as an investment opportunity.

Form 8-K KalVista Pharmaceuticals For- Jun 05

Form 8-K KalVista Pharmaceuticals For: Jun 05 StreetInsider.com

StreetInsider | June 10, 2021

KalVista Pharma's oral KVD900 shows rapid improvement in HAE attacks in mid-stage study

KalVista Pharmaceuticals (KALV) announces clinical data supporting KVD900 as an oral on-demand treatment for hereditary angioedema ((HAE)) at the 12th C1-Inhibitor Deficiency & Angioedema Workshop. An analysis of the pharmacokinetic and pharmacodynamic profile of KVD900 and attack symptom severity in Phase 2 cross-over trial in patients with HAE type I...

Seeking Alpha | June 7, 2021

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop

- KVD900 Efficacious Within First Hours of Attack and Significantly Shortens Time to Improvement of Attack Symptoms - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical

FinanzNachrichten | June 5, 2021

KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop

KVD900 Efficacious Within First Hours of Attack and Significantly Shortens Time to Improvement of Attack Symptoms

BioSpace | June 4, 2021

KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:30 a.m. ET. A live webcast of the presentation will be available on the Companys website at www.kalvista.com. An audio ar

Business Wire | May 27, 2021

Read More 'KALV' Stories Here

KALV Price Returns

1-mo 7.52%
3-mo -8.31%
6-mo 59.26%
1-year 156.45%
3-year 212.14%
5-year 190.17%
YTD 47.60%
2020 6.63%
2019 -9.82%
2018 102.56%
2017 37.91%
2016 -86.05%

Continue Researching KALV

Want to see what other sources are saying about KalVista Pharmaceuticals Inc's financials and stock price? Try the links below:

KalVista Pharmaceuticals Inc (KALV) Stock Price | Nasdaq
KalVista Pharmaceuticals Inc (KALV) Stock Quote, History and News - Yahoo Finance
KalVista Pharmaceuticals Inc (KALV) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9067 seconds.